91-105 of 845

Delivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis
On the Frontlines of SchizophreniaDelivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis

Vitamin D3's Effects on Inflammatory and Oxidative Biomarkers in MS
NeuroFrontiersVitamin D3's Effects on Inflammatory and Oxidative Biomarkers in MS

Iron Deposition and Cognitive Fatigue in Multiple Sclerosis
NeuroFrontiersIron Deposition and Cognitive Fatigue in Multiple Sclerosis

Evaluating Structured Interventions for Cognitive Support in MS
AudioAbstractsEvaluating Structured Interventions for Cognitive Support in MS

Optimizing Vitamin D Supplementation in MS Care
NeuroFrontiersOptimizing Vitamin D Supplementation in MS Care

The Role of Neurofilament Light Chain in MS Management
NeuroFrontiersThe Role of Neurofilament Light Chain in MS Management
- advertisement

Parkinson’s Research in Focus: Translating Science Into Clinical Progress
NeuroFrontiersParkinson’s Research in Focus: Translating Science Into Clinical Progress

Identifying and Managing Violence Risk in Schizophrenia Care
On the Frontlines of SchizophreniaIdentifying and Managing Violence Risk in Schizophrenia Care

Digital Danger: Understanding AI Psychosis in Schizophrenia
On the Frontlines of SchizophreniaDigital Danger: Understanding AI Psychosis in Schizophrenia

Cracking the Migraine Code: How AI May Transform Diagnosis and Treatment
On the Frontlines of MigraineCracking the Migraine Code: How AI May Transform Diagnosis and Treatment

Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
Project Oncology®Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results

Growth Recovery After Tovorafenib in Pediatric Low-Grade Gliomas: New Data
Project Oncology®Growth Recovery After Tovorafenib in Pediatric Low-Grade Gliomas: New Data
- advertisement

Negative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden
On the Frontlines of SchizophreniaNegative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden

Using fMRI to Identify Early Alzheimer’s Disease Subgroups
NeuroFrontiersUsing fMRI to Identify Early Alzheimer’s Disease Subgroups

Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
NeuroFrontiersEvaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease









































